Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19

Phase 2TerminatedNCT04400890

Marvin McCreary, MD105 enrolled

Overview

Resveratrol is a plant polyphenol (that is sold commercially as a supplement) that might help fight coronavirus as well as help protect the body from the effects of disease (COVID-19) caused by the infection. In this proof-of-concept pilot study we will compare the effects of resveratrol to placebo to assess the safety of the resveratrol and explore effectiveness.

This randomized placebo-controlled trial is for the outpatient treatment of (Coronavirus Disease 2019) COVID-19. The purpose of this trial is to evaluate the safety and explore the effectiveness of resveratrol, a plant polyphenol, being re-purposed for patients with early COVID-19. Published in vitro data supports that this polyphenol inhibits coronavirus replication while separately published in silico (computer molecular docking analysis) reports have identified specific molecular targets of resveratrol against (Severe Acute Respiratory Syndrome - Coronavirus 2) SARS-CoV-2. Animal studies also demonstrate that resveratrol is effective at preventing lung injury and death in certain animal models of viral infections. Furthermore, the products long history as an anti-inflammatory might prevent the cytokine storm that is associated with worse outcomes in COVID-19. 200 subjects, 45 and older, (100 receiving the plant polyphenol, 100 receiving placebo) will be enrolled in study to compare whether taking resveratrol will reduce the rate of hospitalization. Subjects will take capsules 4 times a day for a minimum of 7 days (up to 15 days depending on duration of symptoms) plus both groups will receive Vitamin D3 100,000 IU to augment the effects of resveratrol. Resveratrol will be given as 1gm 4 times per day. Placebo tablets will contain brown rice flour in visually identical capsules. The primary outcome measure for this trial is reduction in hospitalization at 21 days from enrollment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

105

Conditions

COVID-19

Interventions

ResveratrolDRUG

Resveratrol vs placebo given for 15 days.

Vitamin D3DIETARY_SUPPLEMENT

Vitamin D3 100,000 IU given on day one.

Eligibility

Sex: ALLMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Outpatients who test positive for infection with SARS-CoV-2. * Age ≥45 years * Mild COVID-19 based on World Health Organization (WHO) Baseline Severity Categorization * Symptom duration ≤ 10 days, or \<72 hours of new respiratory symptoms. * Patient must have access to the internet or a smartphone to complete surveys. * English-speaking patients Exclusion Criteria: * Diagnosed or suspected cognitive impairment that would prevent the patient from cooperating with study procedures, as judged by the screening clinician * Asymptomatic patients (e.g. patients who were screened without symptoms but tested positive) * Known or suspected liver disease or Hepatitis C * Known kidney disease with estimate Glomerular Filtration Rate (eGFR) \<60 * Patients on warfarin, Novel Oral Anticoagulants (NOACs), HIV Protease Inhibitors, immunosuppressants, hydroxychloroquine/chloroquine, and other medication with a narrow therapeutic window. * Allergy to grapes or rice. * Co-morbidities with a high likelihood of hospitalization within 30 days (e.g., current cancer treatment, severe Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)) * Currently pregnant * Hospitalization

Locations (1)

Mt Carmel HealthSystems

Columbus, Ohio, United States

Outcomes

Primary Outcomes

Hospitalization Rates for COVID-19

Number of study participants admitted to the hospital within 21 days of randomization

Time frame: 21 days from study randomization

Secondary Outcomes

ICU Admission Rates

Number of study participants admitted within 21 who subsequently get admitted to the ICU

Time frame: 21 days from randomization

Invasive Ventilation Rates

Number of study participants who get admitted with 21 day of randomization who receiving invasive ventilation.

Time frame: 21 days from randomization

Pneumonia

Number of study participants are diagnosed with pneumonia with 21 day of randomization

Time frame: 21 days from randomization

Pulmonary Embolism

Number of study participants are diagnosed with pulmonary embolism with 21 day of randomization

Time frame: 21 days from start of randomization.

Death

Number of study participants who died with 21 day of randomization

Time frame: Within 21 days from randomization

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.